- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44 result(s) found for: 3D imaging.
Displaying page 1 of 3.
EudraCT Number: 2010-022057-42 | Sponsor Protocol Number: 3D-iUS-NCH | Start Date*: 2011-03-22 | |||||||||||
Sponsor Name:Universität Leipzig | |||||||||||||
Full Title: Pilot study to optimise the use and to evaluate the diagnostic value of intraoperative contrast-enhanced 3D-ultrasound with SonoVue® for imaging of intracranial tumors | |||||||||||||
Medical condition: Patients with an intracranial tumor and planned operation as well as expected echoic behaviour of the tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002779-12 | Sponsor Protocol Number: 10968 | Start Date*: 2023-02-06 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Real-time margin assessment in head and neck cancer – enhancing specificity by combining fresh frozen sectioning with targeted fluorescence imaging The LIGHTNING study | ||
Medical condition: Head and neck cancer for which surgical excision has been determined by the multidisciplinary tumor board | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003216-37 | Sponsor Protocol Number: n.a. | Start Date*: 2015-02-12 |
Sponsor Name: | ||
Full Title: Efficacy of Verapamil/ Verapamil-Kenacort injection versus Kenacort injection in Scar Treatment | ||
Medical condition: Hypertrophic and keloid scars are pathological scars as a result of dermal injury and exhibit exuberant, indefinite growth of collagen during wound healing. Hypertrophic and keloid scars often caus... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001952-16 | Sponsor Protocol Number: PTW-1 | Start Date*: 2021-01-07 |
Sponsor Name:Amsterdam UMC, location VUmc | ||
Full Title: Progesterone for Breast Development in Trans Women; Assessment of effects and safety -a pilot trial- | ||
Medical condition: Hormone treatment of transgender women, we will investigate whether addition of progesterone to estradiol treatment results in an increase of breast volume and if there are side effects. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001296-67 | Sponsor Protocol Number: CBFU | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
Full Title: DUAL ENERGY CONTRAST ENHANCED DIGITAL MAMMOGRAPHY PERFORMANCE EVALUATION IN COMPARISON OF CONVENTIONAL DIGITAL MAMMOGRAPHY, TOMOSINTESIS AND MR IMAGING IN WOMEN FOLLOW-UP FOR BREAST CARCINOMA | |||||||||||||
Medical condition: WOMAN WITH BREAST CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002616-16 | Sponsor Protocol Number: NL49061.031.14 | Start Date*: 2014-07-10 |
Sponsor Name:NKI-AVL | ||
Full Title: Pilot for high-resolution SPECT imaging of breast cancer lumpectomy specimens for 3D identification and quantification of resection margins | ||
Medical condition: Patients with breast cancer, IDC (n=3) and DCIS (n=3) scheduled for a lumpectomy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004991-28 | Sponsor Protocol Number: MD2008-MR-0602 | Start Date*: 2009-03-26 |
Sponsor Name:Medical Faculty Magdeburg | ||
Full Title: Assessment of focal liver lesions in fluoroscopic MR using Primovist and fast dynamic imaging sequences for interventional purposes | ||
Medical condition: The purpose of this study is to evaluate the potential of a better demarcation of liver lesions after injection of the hepatocyte specific contrast agent Gadoxetic acid (Primovist) with fast dynami... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001897-13 | Sponsor Protocol Number: ITM-LET-01 | Start Date*: 2017-08-22 | |||||||||||
Sponsor Name:ITM Solucin GmbH | |||||||||||||
Full Title: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to tar... | |||||||||||||
Medical condition: Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005947-22 | Sponsor Protocol Number: SIPO20 | Start Date*: 2021-11-17 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis | |||||||||||||
Medical condition: Active progressive MS course after an initial relapse clinical course | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003639-59 | Sponsor Protocol Number: 06-RHY-002 | Start Date*: 2007-01-16 | |||||||||||
Sponsor Name:Intercytex | |||||||||||||
Full Title: A phase IIa open-label dose-escalation study using ICX-RHY to enhance the aesthetic appearance of nasolabial folds | |||||||||||||
Medical condition: Moderately severe wrinkles | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002329-27 | Sponsor Protocol Number: ETLAS-2 | Start Date*: 2020-12-10 | ||||||||||||||||
Sponsor Name:Herlev Gentofte Hospital | ||||||||||||||||||
Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial. | ||||||||||||||||||
Medical condition: Cerebral small vessel disease and stroke. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001709-25 | Sponsor Protocol Number: CCR5119 | Start Date*: 2020-02-06 |
Sponsor Name:The Institute of Cancer Research | ||
Full Title: Randomised phase II trial testing efficacy of intra-tumoural hydrogen peroxide as a radiation sensitiser in patients with locally advanced/recurrent breast cancer | ||
Medical condition: Patients with locally advanced/recurrent breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004143-36 | Sponsor Protocol Number: CL2-42909-016 | Start Date*: 2017-05-30 | |||||||||||
Sponsor Name:Ilkos Thérapeutique Inc. | |||||||||||||
Full Title: Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer. A 10-week randomized, double-blind, placebo-controlled... | |||||||||||||
Medical condition: Venous leg ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DK (Prematurely Ended) CZ (Completed) SK (Completed) ES (Completed) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005193-26 | Sponsor Protocol Number: P160407 | Start Date*: 2022-04-25 |
Sponsor Name:ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (AP-HP) | ||
Full Title: 18F]–Fludarabine PET/MR imaging for the assessment of newly-diagnosed primary central nervous system (CNS) lymphoma: a pilot PET/MR study | ||
Medical condition: Patients with newly diagnosed primary lymphoma of the central nervous system who have not been treated with surgery, radiotherapy or chemotherapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003876-22 | Sponsor Protocol Number: CCDZ173X2201 | Start Date*: Information not available in EudraCT |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CD... | ||
Medical condition: APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) NL (Completed) IE (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002304-16 | Sponsor Protocol Number: 130873-2004 | Start Date*: 2005-06-14 |
Sponsor Name:South Tees Hospitals NHS Foundation Trust | ||
Full Title: The STARS (STeroids Against Re-Stenosis) Trial [THE USE OF Peri-PROCEDURAL ORAL CORTICOSTERIODS TO PREVENT IN-SEGMENT RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION.] | ||
Medical condition: coronary artery disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001464-19 | Sponsor Protocol Number: GE-122-020 | Start Date*: 2016-02-11 | ||||||||||||||||
Sponsor Name:GE Healthcare Ltd. and its affiliates | ||||||||||||||||||
Full Title: AdreView™ Myocardial Imaging for Risk Evaluation – A multicentre trial to guide ICD implantation in NYHA class II & III heart failure patients with 30%≤LVEF≤35% ADMIRE-ICD | ||||||||||||||||||
Medical condition: Heart failure | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-001624-14 | Sponsor Protocol Number: LE3301 | Start Date*: 2022-11-15 | |||||||||||
Sponsor Name:Pharming Technologies B.V. | |||||||||||||
Full Title: An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kina... | |||||||||||||
Medical condition: Activated Phosphoinositide 3-Kinase Delta Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000331-41 | Sponsor Protocol Number: CHDR1430 | Start Date*: 2016-03-22 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: A randomized, open-label, vehicle-controlled, parallel, dose-ranging study to assess the pharmacodynamics of topically applied Imiquimod in healthy volunteers | |||||||||||||
Medical condition: none, this is a study on healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004579-37 | Sponsor Protocol Number: MZ12-PCP-PalenicekTomas-A | Start Date*: 2014-06-18 |
Sponsor Name:National Institute of Mental Health | ||
Full Title: Animal and human serotonergic model of schizophrenia: validity evaluated by qEEG and fMRI | ||
Medical condition: Inclusion criteria: a) Men and women at age between 28 and 65 years b) healthy volunteers with negative psychiatric history (severe mental illnesses that meet the criteria of ICD 10 F0.X - F99.X) ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
